Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Atopic Dermatitis Clinical Trial

Official title:

Clinical and Molecular Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response or Facial Erythema After Treatment With Dupilumab

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05602207
• Other study ID #: Inno-6050
• Status: Recruiting
• Phase: Phase 4
• Start date: November 25, 2022
• Est. completion date: August 2025

Study information

• Verified date: April 2023
• Source: Innovaderm Research Inc.
• Contact: Dominique Dufour Bergeron
• Phone: 1-866-575-3111
• Email: ddbergeron[@]innovaderm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.

Description:

This study is being conducted to evaluate the efficacy, safety, and molecular effects of abrocitinib in subjects with an unsatisfactory response or facial erythema after at least 12 weeks of treatment with dupilumab. Approximately 60 subjects with atopic dermatitis will receive abrocitinib once daily for 12 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 2025
• Est. primary completion date: July 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female subject 18 years of age or older, at the time of consent.

2. Subject has clinically confirmed diagnosis of active atopic dermatitis (AD), according to Hanifin and Rajka criteria.

3. Subject has at least a 1-year history of AD and had no significant flares in AD for at least 4 weeks before screening.

4. Subjects who had moderate to severe AD before initiating dupilumab treatment.

5. Subject currently has an unsatisfactory response or facial erythema after at least 12 weeks of treatment with dupilumab, defined as follows:

1. A global vIGA-AD = 2, at least 1% BSA with facial erythema, and a modified vIGA-AD for the face =2 at screening and Day 1 OR

2. A global vIGA-AD = 2, at least 3% BSA affected by AD on the trunk and/or limbs, and a modified vIGA-AD for the trunk/limbs = 2 at screening and Day 1.

Exclusion Criteria:

1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.

2. Subject has clinically infected AD.

3. Subject has a history of skin disease or presence of skin condition that would interfere with the study assessments.

4. Subject has a history of cancer within 5 years prior to Day 1.

5. Subject has a history of lymphoproliferative disorder, lymphoma, or leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.

6. Subject has any clinically significant medical condition that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.

7. Subject is known to have immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.

8. Subject has a current or recent clinically serious infection.

9. Subject has used abrocitinib prior to Day 1.

10. Subject has a known hypersensitivity to abrocitinib or its excipients.

11. Subject has a known history of clinically significant drug or alcohol abuse within 6 months prior to Day 1 that in the opinion of the investigator will preclude participation in the study.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• Abrocitinib
100 mg Abrocitinib once daily (QD) for 12 weeks

Locations

Country	Name	City	State
Canada	Inno-6050 Site 10	Montreal	Quebec
Canada	Inno-6050 Site 18	Newmarket	Ontario
Canada	Inno-6050 Site 14	Québec	Quebec
Canada	Inno-6050 Site 20	Québec	Quebec
Canada	Inno-6050 Site 11	Toronto	Ontario
Canada	Inno-6050 Site 15	Winnipeg	Manitoba
United States	Inno-6050 Site 17	Auburn Hills	Michigan
United States	Inno-6050 Site 22	Birmingham	Alabama
United States	Inno-6050 Site 13	Fountain Valley	California
United States	Inno-6050 Site 21	Miami Lakes	Florida
United States	Inno-6050 Site 16	Quincy	Massachusetts
United States	Inno-6050 Site 19	Saint Petersburg	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Innovaderm Research Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline of Eczema Area and Severity Index (EASI)	The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, induration/infiltration (papules), excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percentage of body surface area (BSA) involved for each body region and for the proportion of the body region to the whole body.; The primary endpoint is the change from baseline in EASI at Week 12.	at Week 12
Secondary	Change from baseline of Validated Investigator Global Assessment for atopic dermatitis (vIGA-AD)	The vIGA-AD is a global assessment of the current state of the disease. It is a 5-point morphological assessment of overall disease severity.	at Week 12
Secondary	Change from baseline of Body Surface Area (BSA)	The overall BSA affected by disease will be evaluated (from 0% to 100%). The palmar surface of one hand (using the patient's hand and including the fingers) represents 1% of the total BSA.	at Week 12
Secondary	Change from baseline of Peak pruritus Numerical Rating Scale (NRS)	The intensity of pruritus will be evaluated using a NRS by asking subjects to assign a numerical score representing of the worst intensity over the last 24 hours of their symptoms on a scale from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms.	over 12 weeks
Secondary	Change from baseline of Facial Eczema Area and Severity Index (EASI)	The facial EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, induration/infiltration (papules), excoriation, and lichenification (each scored from 0 to 3 separately) for each of six facial regions, with adjustment for the percentage of facial surface area involved for each facial region, using the "rule of fours".	at Week 12
Secondary	Change from baseline of Modified validated Investigator Global Assessment for atopic dermatitis (vIGA-AD)	The modified vIGA-AD will be used to assess the severity of lesions on the face for subjects with facial erythema at baseline and on the trunk and/or limbs for subjects with atopic dermatitis (AD) on those body parts at baseline.	at Week 12
Secondary	Change from baseline of the CCL18 Skin Biomarker Level	The molecular effects of abrocitinib will be evaluated by measuring changes from baseline in CCL18 skin biomarker levels in lesional and nonlesional skin samples.	at Week 12
Secondary	Change from baseline of the MMP12 Skin Biomarker Level	The molecular effects of abrocitinib will be evaluated by measuring changes from baseline in MMP12 skin biomarker levels lesional and nonlesional skin samples.	at Week 12
Secondary	Change from baseline of the Keratin 16 Skin Biomarker Level	The molecular effects of abrocitinib will be evaluated by measuring changes from baseline in Keratine 16 skin biomarker levels lesional and nonlesional skin samples.	at Week 12
Secondary	Change from baseline of the S100A7 Skin Biomarker Level	The molecular effects of abrocitinib will be evaluated by measuring changes from baseline in S100A7 skin biomarker levels lesional and nonlesional skin samples.	at Week 12
Secondary	Change from baseline of the S100A8 Skin Biomarker Level	The molecular effects of abrocitinib will be evaluated by measuring changes from baseline in S100A8 skin biomarker levels lesional and nonlesional skin samples.	at Week 12
Secondary	Change from baseline of the S100A9 Skin Biomarker Level	The molecular effects of abrocitinib will be evaluated by measuring changes from baseline in S100A9 skin biomarker levels lesional and nonlesional skin samples.	at Week 12